Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Invivyd, Inc. - Common Stock (NQ: IVVD )

0.9650 -0.0350 (-3.50%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Invivyd, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference
From Invivyd
Via GlobeNewswire
Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024
From Invivyd
Via GlobeNewswire
Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability
From Invivyd
Via GlobeNewswire
Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants
From Invivyd
Via GlobeNewswire
Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024
From Invivyd
Via GlobeNewswire
Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data
From Invivyd
Via GlobeNewswire
Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)
From Invivyd
Via GlobeNewswire
Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19
From Invivyd
Via GlobeNewswire
Invivyd to Participate in Upcoming Investor Conferences
From Invivyd
Via GlobeNewswire
Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™
From Invivyd
Via GlobeNewswire
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest
From Invivyd
Via GlobeNewswire
Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial
From Invivyd
Via GlobeNewswire
Invivyd Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From Invivyd
Via GlobeNewswire
Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
Invivyd Announces its Addition to the Russell 2000® and Russell 3000® Indexes
From Invivyd
Via GlobeNewswire
Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants
From Invivyd
Via GlobeNewswire
Invivyd to Participate at the Jefferies Global Healthcare Conference
From Invivyd
Via GlobeNewswire
Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial
From Invivyd
Via GlobeNewswire
Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer
From Invivyd
Via GlobeNewswire
Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)
From Invivyd
Via GlobeNewswire
Invivyd Elects Two New Independent Members to its Board of Directors
From Invivyd
Via GlobeNewswire
Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
From Invivyd
Via GlobeNewswire
Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights
From Invivyd
Via GlobeNewswire
Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback
From Invivyd
Via GlobeNewswire
Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position
From Invivyd
Via GlobeNewswire
Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™
From Invivyd
Via GlobeNewswire
Invivyd Announces CEO Transition
Jeremy Gowler appointed Interim CEO 
From Invivyd
Via GlobeNewswire
Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million
From Invivyd
Via GlobeNewswire
Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights
From Invivyd
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.